Search company, investor...

Metabasis Therapeutics

mbasis.com

Founded Year

1997

Stage

Acq - P2P | Acquired

Total Raised

$105.84M

About Metabasis Therapeutics

Biopharmaceutical company developing products for diabetes, hepatitis, liver cancer, and other liver-related diseases.

Headquarters Location

11119 North Torrey Pines Road

La Jolla, California, 92037,

United States

858-587-2770

Missing: Metabasis Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metabasis Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metabasis Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabasis Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,903 items

Metabasis Therapeutics Patents

Metabasis Therapeutics has filed 27 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Cannabinoids
  • Designer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/24/2017

6/7/2022

Prodrugs, Rare diseases, Human proteins, Fatty acids, Mammal male reproductive system

Grant

Application Date

4/24/2017

Grant Date

6/7/2022

Title

Related Topics

Prodrugs, Rare diseases, Human proteins, Fatty acids, Mammal male reproductive system

Status

Grant

Latest Metabasis Therapeutics News

Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors

Apr 18, 2022

Seasoned biotech entrepreneur and CEO will support Stemson’s efforts to develop the first iPSC-derived cell therapy to treat hair loss April 18, 2022 12:00 PM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )-- Stemson Therapeutics Corp., a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board. “We welcome Paul as an important addition to our board of directors,” said Matt Posard, Stemson’s executive chairman of the board. “With more than 35 years of experience founding and leading therapeutics development companies from preclinical to clinical stage development and from start-up through IPO, Paul will provide valuable guidance to accelerate Stemson’s progress.” “I am delighted and honored to join Stemson’s Board of Directors,” said Paul. “Stemson’s unique combination of novel technologies to bioengineer hair follicles not only has the potential to help millions of people suffering from hair loss, but can more broadly advance the capabilities for cell therapy development across the industry. I look forward to working with the team and supporting their journey.” Paul Laikind, PhD, was CEO of ViaCyte from 2012 until 2020, where he lead the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of Type 1 Diabetes. Paul led the company from the preclinical stage through the introduction of two product candidates into clinical trials before retiring at the end of 2020. A third product that Viacyte developed in collaboration with CRISPR Tx recently also entered clinical development. Dr. Laikind served as Chief Business Officer and Senior Vice President of the Sanford Burnham Medical Research Institute from 2009 – 2011, focusing on enhancing the translational capabilities of the institute. From 1999 - 2009, Paul was cofounder and CEO of Metabasis Therapeutics, which concentrated on therapeutics development for metabolic and liver diseases. He took Metabasis from founding through IPO, and from preclinical to clinical stage development, with five products in the clinic. From 1986 – 1999, Paul cofounded and served as Vice President of Corporate Development at Gensia Pharmaceuticals where they developed small molecule therapies for the treatment of cardiovascular, neurological and inflammatory diseases. During that time, he cofounded and served as an advisor to Viagene from 1988 – 1994, the first commercially focused gene therapy company developing proprietary gene delivery technology to treat HIV, cancer and inherited disorders. Gensia, Viagene and Metabasis each completed successful initial public offerings and were eventually acquired for combined proceeds of over $3.5 billion. Throughout his career, Dr. Laikind has played a leadership role in the evolving biotechnology industry. He serves or has served on the board of industry organizations including BIO, BIOCOM, CONNECT, and Alliance for Regenerative Medicine. Paul earned his PhD in Biochemistry from the University of California, San Diego, and is a veteran of the US Navy. “We are very lucky to have Paul join us. The next stage of Stemson’s development is to advance our first product toward human clinical trials,” stated Geoff Hamilton, cofounder and CEO of Stemson Therapeutics. “Paul’s tremendous business leadership experience and industry relationships, as well as his involvement developing similar technologies to Stemson’s while at ViaCyte, will help us guide the company toward that goal.” About Stemson Therapeutics Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia . Today, there are no available treatments capable of growing new hair follicles. Stemson’s world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit www.stemson.com . Contacts

Metabasis Therapeutics Frequently Asked Questions (FAQ)

  • When was Metabasis Therapeutics founded?

    Metabasis Therapeutics was founded in 1997.

  • Where is Metabasis Therapeutics's headquarters?

    Metabasis Therapeutics's headquarters is located at 11119 North Torrey Pines Road, La Jolla.

  • What is Metabasis Therapeutics's latest funding round?

    Metabasis Therapeutics's latest funding round is Acq - P2P.

  • How much did Metabasis Therapeutics raise?

    Metabasis Therapeutics raised a total of $105.84M.

  • Who are the investors of Metabasis Therapeutics?

    Investors of Metabasis Therapeutics include Ligand Pharmaceuticals, InterWest Partners, MPM Capital, Sprout Group, Domain Associates and 18 more.

  • Who are Metabasis Therapeutics's competitors?

    Competitors of Metabasis Therapeutics include Oxurion, PDS Biotechnology, CureDM, Idenix Pharmaceuticals, NewLink Genetics and 10 more.

Compare Metabasis Therapeutics to Competitors

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

T
Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

E
Effigene Pharmaceuticals

Effigene Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company developing small interference RNA (siRNA)-based therapeutics to treat various human diseases.

Kylin Therapeutics Logo
Kylin Therapeutics

Kylin Therapeutics, a biotechnology company, employs a RNA nanoparticle technology platform called"pRNA" to exploit the potential of RNA interference (RNAi) for treatment of many common diseases including cancer.

K
Kibow Biotech

Kibow Biotech, Inc. develops groundbreaking methods of using probiotics (beneficial bacteria) to bring hope to kidney failure patients worldwide. With the company's scientifically formulated dietary supplements, the company also address metabolic syndrome patients who are at an elevated long-term risk of developing chronic kidney failure (CKF).

Protemix Logo
Protemix

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.